Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 5, 2026, 4:41 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 69 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: New Formulation Placebo Clear all
Completed Not applicable Interventional Accepts healthy volunteers

RCT of an Oral Acne Supplement for Adult Women

NCT06097871
View directory record Official record
Conditions
Acne
Interventions
Skin Nutraceutical Supplement, Placebo pill
Dietary Supplement · Other
Lead sponsor
Nutraceutical Wellness Inc.
Industry
Eligibility
18 Years to 50 Years · Female only
Enrollment
102 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
High Point, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 24, 2024 · Synced Sep 5, 2026, 4:41 AM EDT
Completed Early Phase 1 Interventional

BXQ-350 Pharmacokinetic/Pharmacodynamic Study in Cancer Patients

NCT05291286
View directory record Official record
Conditions
Neuropathy;Peripheral, Chemotherapy-induced Peripheral Neuropathy
Interventions
BXQ-350, Placebo
Drug · Other
Lead sponsor
Bexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
3
States / cities
Cincinnati, Ohio • Columbus, Ohio • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 26, 2025 · Synced Sep 5, 2026, 4:41 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Two-part Study to Compare a Tablet and Capsule Formulation of GSK2838232 With and Without Food, and to Assess the Safety and Drug Levels of Repeated Once-daily Doses of GSK2838232 Without Ritonavir

NCT03234036
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus, HIV Infections
Interventions
GSK2838232 100 mg tablet, GSK2838232 50 mg capsule, Ritonavir 100 mg tablets, Placebo for GSK2838232 tablets
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 27, 2020 · Synced Sep 5, 2026, 4:41 AM EDT
Completed Phase 2 Interventional Results available

Dose-finding Study of New Tolvaptan Formulation in Subjects With ADPKD

NCT01210560
View directory record Official record
Conditions
Autosomal Dominant Polycystic Kidney Disease
Interventions
Tolvaptan MR, Tolvaptan IR
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
6
States / cities
Boston, Massachusetts • Minneapolis, Minnesota • Rochester, Minnesota + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 13, 2018 · Synced Sep 5, 2026, 4:41 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

The Effects of GLA on Human Volunteers

NCT01397604
View directory record Official record
Conditions
Healthy Volunteers
Interventions
GLA-AF, GLA-SE, Squalene
Drug · Other
Lead sponsor
Rockefeller University
Other
Eligibility
18 Years to 60 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 22, 2013 · Synced Sep 5, 2026, 4:41 AM EDT
Recruiting Phase 1Phase 2 Interventional

Study of ATX-01 in Participants With DM1

NCT06300307
View directory record Official record
Conditions
Myotonic Dystrophy 1
Interventions
ATX-01, Placebo
Drug
Lead sponsor
ARTHEx Biotech S.L.
Industry
Eligibility
18 Years to 64 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
5
States / cities
Los Angeles, California • Gainesville, Florida • Iowa City, Iowa + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2026 · Synced Sep 5, 2026, 4:41 AM EDT
Terminated Phase 3 Interventional Results available

An Efficacy, Safety and Tolerability Study of Glatiramer Acetate (GA) 20 mg/0.5 ml New Formulation Administered Daily by Subcutaneous (SC) Injection in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)

NCT01578785
View directory record Official record
Conditions
Relapsing-Remitting Multiple Sclerosis
Interventions
Glatiramer Acetate, Placebo
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
178 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
25
States / cities
Cullman, Alabama • Fresno, California • La Jolla, California + 17 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2014 · Synced Sep 5, 2026, 4:41 AM EDT
Completed Phase 3 Interventional Results available

Study to Assess the Safety and Efficacy of Modified-Release Prednisone (Lodotra®) Therapy in Patients With Active Rheumatoid Arthritis

NCT00650078
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
MR prednisone, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 80 Years
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
28
States / cities
Huntsville, Alabama • Phoenix, Arizona • Los Angeles, California + 22 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2024 · Synced Sep 5, 2026, 4:41 AM EDT
Completed Phase 3 Interventional Results available

A Study to Assess Safety and Efficacy of Risankizumab Using a New Formulation in Participants With Moderate to Severe Plaque Psoriasis

NCT03875482
View directory record Official record
Conditions
Psoriasis
Interventions
Risankizumab, Placebo solution for risankizumab
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
157 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
40
States / cities
Birmingham, Alabama • Phoenix, Arizona • Rogers, Arkansas + 35 more
Source: ClinicalTrials.gov public record
Updated Mar 15, 2021 · Synced Sep 5, 2026, 4:41 AM EDT
Completed Not applicable Interventional Results available

Test on a New Experimental Mouth Rinse for Relieving Tooth Sensitivity

NCT02113579
View directory record Official record
Conditions
Dentin Sensitivity
Interventions
Experimental Mouth Rinse 12027-033, Placebo Mouth Rinse
Device · Other
Lead sponsor
Johnson & Johnson Consumer and Personal Products Worldwide
Industry
Eligibility
18 Years and older
Enrollment
375 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
2
States / cities
Fort Wayne, Indiana • Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Jun 9, 2015 · Synced Sep 5, 2026, 4:41 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Comparison of the Safety and Immunogenicity of Various Schedules of Dengue Vaccine in Healthy Adult Volunteers

NCT01542632
View directory record Official record
Conditions
Healthy
Interventions
Takeda's Tetravalent Dengue Vaccine Candidate (TDV), TDV New Formulation, Placebo, New Formulation Placebo
Biological · Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 45 Years
Enrollment
140 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
3
States / cities
Fort Collins, Colorado • Galveston, Texas • West Jordan, Utah
Source: ClinicalTrials.gov public record
Updated Jul 17, 2019 · Synced Sep 5, 2026, 4:41 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Multiple Ascending Dose Study to Assess the Pharmacokinetics, Safety, and Tolerability of Orally Administered SYN 020

NCT05045833
View directory record Official record
Conditions
Enteritis Caused by Radiation
Interventions
SYN-020 Delayed Release Capsule
Drug
Lead sponsor
Theriva Biologics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
West Bend, Wisconsin
Source: ClinicalTrials.gov public record
Updated Apr 20, 2022 · Synced Sep 5, 2026, 4:41 AM EDT
Completed Phase 3 Interventional Results available

A Pivotal Efficacy Trial to Evaluate HLD200 in Children With ADHD in a Naturalistic Setting

NCT02520388
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
HLD200 methylphenidate hydrochloride (MPH) Capsules, Placebo
Drug
Lead sponsor
Ironshore Pharmaceuticals and Development, Inc
Other
Eligibility
6 Years to 12 Years
Enrollment
163 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
21
States / cities
Newport Beach, California • Bradenton, Florida • Gainesville, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2021 · Synced Sep 5, 2026, 4:41 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study Evaluating the Safety and Tolerability of a New Intravenous Formulation of MOA-728 in Healthy Subjects

NCT00464802
View directory record Official record
Conditions
Healthy
Interventions
MOA-728
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Nov 24, 2019 · Synced Sep 5, 2026, 4:41 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Clinical Investigation of Galnobax® for the Treatment of Diabetic Foot Ulcers

NCT01113515
View directory record Official record
Conditions
Diabetic Foot Ulcer
Interventions
Esmolol hydrochloride, Placebo gel
Drug
Lead sponsor
Novalead Pharma Private Limited
Industry
Eligibility
18 Years to 95 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated May 19, 2024 · Synced Sep 5, 2026, 4:41 AM EDT
Recruiting Phase 2 Interventional

Evaluating the Impact of a Novel Cannabinoid Product for Endometriosis

NCT06477406
View directory record Official record
Conditions
Endometriosis
Interventions
Cannabidiol, Placebo
Drug
Lead sponsor
Mclean Hospital
Other
Eligibility
21 Years and older · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Belmont, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Sep 5, 2026, 4:41 AM EDT
Completed Phase 2 Interventional Results available

A Phase 2 Study of Cladribine Add-on to Interferon-beta (IFN-beta) Therapy in Multiple Sclerosis (MS) Subjects With Active Disease (ONWARD)

NCT00436826
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Cladribine, Placebo, Interferon-beta (IFN-beta)
Drug
Lead sponsor
EMD Serono Research & Development Institute, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
172 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
21
States / cities
Cullman, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 18 more
Source: ClinicalTrials.gov public record
Updated Oct 11, 2020 · Synced Sep 5, 2026, 4:41 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of LY3039478 in Healthy Participants

NCT02659865
View directory record Official record
Conditions
Healthy
Interventions
Placebo, LY3039478 Capsule Formulation (Formulation 3), LY3039478 Drug-in Capsule (Reference, Formulation 1), LY3039478 Formulated Capsule (Test, Formulation 3)
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Daytona Beach, Florida
Source: ClinicalTrials.gov public record
Updated Aug 11, 2025 · Synced Sep 5, 2026, 4:41 AM EDT
Completed Phase 2 Interventional

PHASE IIA: Trial of a Novel Ondansetron Formulation (OND-PR002) and Immediate-Release Methylphenidate (Ritalin®)(OND003IND)

NCT01377662
View directory record Official record
Conditions
Methamphetamine Dependence, Cocaine Dependence
Interventions
OND-PR002 and MPh-IR, Placebo: Two dextrose capsules for Ond-PR002 and MPh-IR
Drug · Other
Lead sponsor
Tong Lee
Other
Eligibility
18 Years to 45 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
3
States / cities
Durham, North Carolina • Raleigh, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 6, 2014 · Synced Sep 5, 2026, 4:41 AM EDT
Terminated Phase 3 Interventional Results available

Study Evaluating The Efficacy Of A Novel Ibuprofen Formulation On Fever In Patients With An Uncomplicated Acute Infection

NCT01035346
View directory record Official record
Conditions
Infection
Interventions
Ibuprofen, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
12 Years to 65 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
5
States / cities
Cypress, California • Westlake Village, California • Omaha, Nebraska + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2012 · Synced Sep 5, 2026, 4:41 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Safety, Tolerability and Pharmacokinetics of a New Formulation of Oritavancin in Healthy Volunteers

NCT02471690
View directory record Official record
Conditions
Healthy
Interventions
Oritavancin, Dextrose
Drug
Lead sponsor
The Medicines Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
West Bend, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 18, 2023 · Synced Sep 5, 2026, 4:41 AM EDT
Not yet recruiting Not applicable Interventional

Probiotic Milk Drink for Gut and Brain Health in Older Adults and Caregivers

NCT07800195
View directory record Official record
Conditions
Alzheimer Disease Related Dementia
Interventions
Probiotic Fermented Milk (PFM) Drink, Placebo
Dietary Supplement
Lead sponsor
University of South Florida
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Sep 5, 2026, 4:41 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Determination of the Safety and Efficacy of a Novel Oral Rinse on Oral Health

NCT04197427
View directory record Official record
Conditions
Plaque, Gingivitis
Interventions
Experimental Oral Rinse, Placebo
Device
Lead sponsor
You First Services
Industry
Eligibility
18 Years to 75 Years
Enrollment
62 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Dec 16, 2019 · Synced Sep 5, 2026, 4:41 AM EDT
Completed Phase 3 Interventional Results available

Adaptive COVID-19 Treatment Trial 2 (ACTT-2)

NCT04401579
View directory record Official record
Conditions
COVID-19
Interventions
Placebo, Remdesivir, Baricitinib
Other · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 99 Years
Enrollment
1,033 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
53
States / cities
Birmingham, Alabama • La Jolla, California • Los Angeles, California + 44 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2022 · Synced Sep 5, 2026, 4:41 AM EDT